ACRS

SEC source: 0001209191-23-016065 · doc4.xml · derivative · entry 8

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

SEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 3

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 2

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016065 · doc4.xml · nonDerivative · entry 1

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 9

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock · 24,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F8 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

F8 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

SEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 8

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,550

Underlying: Common Stock · 18,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F7 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

F7 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

SEC source: 0001209191-23-016074 · doc4.xml · derivative · entry 7

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 96,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

F6 · derivative.expiration_date: The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.

SEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 3

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,314,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 2

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,290,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016074 · doc4.xml · nonDerivative · entry 1

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,271,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 9

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,125

Underlying: Common Stock · 2,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F8 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F8 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 8

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200

Underlying: Common Stock · 1,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F7 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F7 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 7

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,475 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 3

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,175

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-010658 · doc4.xml · nonDerivative · entry 1

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,386

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.79 to $13.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-008451 · doc4.xml · nonDerivative · entry 1

Loerop James · CIK 0001781549 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,983

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2023 pursuant to preexisting sell-to-cover elections.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.80 to $13.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 5

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,175,763

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

SEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 4

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,175,963

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.51 to $17.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

SEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 3

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,179,084

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.27 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

SEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 2

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,179,684

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.25 to $15.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-007013 · doc4.xml · derivative · entry 2

Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-007013 · doc4.xml · derivative · entry 1

Manion Douglas J. · CIK 0001875875 · Director · Pres and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,000

Underlying: Common Stock · 378,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-007023 · doc4.xml · derivative · entry 2

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-007023 · doc4.xml · derivative · entry 1

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 4

Loerop James · CIK 0001781549 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,750

Underlying: Common Stock · 11,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

SEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 3

Loerop James · CIK 0001781549 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 2

Loerop James · CIK 0001781549 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-01-31

F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006999 · doc4.xml · nonDerivative · entry 1

Loerop James · CIK 0001781549 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

SEC source: 0001209191-23-007032 · doc4.xml · nonDerivative · entry 1

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,180,763

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.28 to $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-006982 · doc4.xml · derivative · entry 2

Cawkwell Gail · CIK 0001761167 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006982 · doc4.xml · derivative · entry 1

Cawkwell Gail · CIK 0001761167 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006969 · doc4.xml · derivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-006969 · doc4.xml · derivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

SEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 3

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,205,763

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 2

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,220,763

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.92 to $16.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-001329 · doc4.xml · nonDerivative · entry 1

Walker Neal · CIK 0001604457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,381

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.89 to $15.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-061695 · doc4.xml · nonDerivative · entry 1

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,386

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.56 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 3

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 434,455

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 2

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 435,826

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-056644 · doc4.xml · nonDerivative · entry 1

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 476,986

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.165, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-004300 · doc4.xml · nonDerivative · entry 1

Powell Andrew Kenneth William · CIK 0001304113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,856

SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 3

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 488,381

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 2

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 502,921

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-054675 · doc4.xml · nonDerivative · entry 1

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 514,939

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-054075 · doc4.xml · nonDerivative · entry 2

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 529,555

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.23 to $17.1023, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-054075 · doc4.xml · nonDerivative · entry 1

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 561,648

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-054073 · doc4.xml · nonDerivative · entry 1

Monahan Joseph · CIK 0001861790 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,386

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.72 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-053312 · doc4.xml · nonDerivative · entry 1

SCHIFF ANDREW N · CIK 0001172252 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Aisling Capital IV LP

Disclosed balance after: 581,592

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Aisling Capital IV, LP on August 23, 2022.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.